Should apixaban (Eliquis) be discontinued before holmium laser enucleation of the prostate?

Should Eliquis (Apixaban) Be Held Before HoLEP?

Yes, apixaban should be discontinued 48 hours prior to holmium laser enucleation of the prostate (HoLEP), though the procedure can be safely performed even if anticoagulation is continued.

Primary Recommendation

The FDA label for Eliquis explicitly states that ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 1. This is your baseline guidance for perioperative management.

Risk Stratification for HoLEP

The evidence shows that laser prostate surgery (including HoLEP) can be safely accomplished without discontinuing anticoagulation in patients at significant thrombotic risk 2. However, the data demonstrates nuanced differences:

When Apixaban is Held (Preferred Approach):

• Discontinue 48 hours before surgery if creatinine clearance >30 mL/min 1
• No bridging anticoagulation is required 1
• Resume apixaban after adequate hemostasis is established 1
• Most recent high-quality study (2025) showed no significant differences in bleeding outcomes between held vs. continued apixaban for HoLEP 3

When Apixaban is Continued:

• The 2025 retrospective analysis of 139 patients found HoLEP is "safe and efficacious whether APAC is held or continued" 3
• However, patients who held anticoagulation had trends toward better outcomes (shorter stays, earlier catheter removal) 3
• Multiple studies confirm laser prostatectomy can be performed on continued anticoagulation without intraoperative transfusions 2

Practical Algorithm

For patients on apixaban undergoing HoLEP:

1. Assess thrombotic risk:

   • High risk (recent stroke, mechanical valve, recent VTE <3 months): Consider continuing apixaban or very short hold (24 hours)
   • Standard risk (atrial fibrillation, remote VTE): Hold 48 hours

2. Check renal function:

   • CrCl >50 mL/min: Hold 48 hours (2 days before surgery)
   • CrCl 30-50 mL/min: Hold 72 hours (3 days before surgery) 4

3. Day of surgery:

   • Verify last dose was >48 hours ago
   • Proceed with HoLEP

4. Postoperative resumption:

   • Resume apixaban when adequate hemostasis achieved (typically 12-24 hours post-op) 1
   • No bridging needed 1

Evidence Quality and Nuances

The 2014 ICUD/AUA guidelines specifically state that laser prostatectomy can be performed with therapeutic anticoagulation 2, distinguishing it from TURP which has significantly higher bleeding risk. However, the FDA label takes precedence and recommends holding for 48 hours 1.

The most recent 2025 study directly comparing held vs. continued apixaban in HoLEP found no significant differences in transfusion rates, complications, or bleeding events 3. A 2019 study showed slightly higher rates of bladder tamponade (7.9% vs 2.2%) and transfusions (1.3% vs 0.2%) when DOACs were held and bridged, though absolute numbers remained low 5.

Critical Caveats

• Do NOT bridge with heparin - this is unnecessary and increases bleeding risk 1
• Verify the 48-hour window - studies show 94% of patients achieve clinically insignificant anticoagulation levels after 48 hours 6
• HoLEP is NOT the same as TURP - TURP has much higher bleeding risk and different anticoagulation management 2
• Consider P-gp inhibitors - if patient is on drugs like ketoconazole or ritonavir, apixaban levels may be higher and require longer discontinuation 1

Bottom Line

Hold apixaban 48 hours before HoLEP in most patients per FDA guidance 1, but recognize that continuing anticoagulation is a reasonable alternative in very high thrombotic risk patients given the hemostatic advantages of laser enucleation 2, 3. The decision should weigh the patient's specific thrombotic risk against the minimal incremental bleeding risk, with the 48-hour hold being the standard, safest approach for most patients.